在接受抗CD25+rATG免疫治疗的胰岛同种异体移植术患者体内FoxP3+T细胞增加，而不是CD25+T细胞
发布时间：2012-10-08 14:17:02浏览次数：2725次来源：吉林大学白求恩第二医院 上海市第六人民医院 摘自:2012;274(1-2):83-8. Epub 2012 Feb 6.Abstract
对于接受胰岛同种异体移植术后的1型糖尿病患者，抗CD25抗体可以作为一种诱导疗法。尽管先前的报道提示抗CD25疗法可能会导致CD4 + CD25 +调节性T细胞的耗竭，并质疑该疗法对提高移植耐受性的作用，但是抗CD25抗体对调节性T细胞的数量和功能的影响仍不清楚。我们对一项单中心研究中登记的胰岛同种异体移植接受者使用赛尼哌（daclizumab）（一种抗CD25抗体）的患者检测其对体内调节性T细胞（Tregs）的影响，并在移植后继续监测。我们的数据显示，观察到的移植术后CD25+调节性T细胞（Tregs）的减少是因为赛尼哌（daclizumab）屏蔽了CD25受体，而不是CD25+调节性T细胞（Tregs）的耗竭。此外，利用调节性T细胞标记物FoxP3，我们发现抗CD25+ATG疗法导致移植术后FoxP3调节性T细胞（Tregs）的增长。这些数据表明，以抗CD25为基础的治疗对调节性T细胞存在有益作用，抗CD25联合ATG疗法可能会成为对自身免疫性疾病和移植的一种很有前途的治疗方法。
FoxP3+, and not CD25+, T cells increase post-transplant in islet allotransplant recipients following anti-CD25+ rATG immunotherapy.
Anti-CD25 antibodies are used as an induction therapy in islet allotransplantation for type 1 diabetes. Although previous reports suggested that anti-CD25 treatment may lead to depletion of CD4+CD25+ regulatory T cells (Tregs) and questioned its use in tolerance-promoting protocols for transplantation, the effect of anti-CD25 antibodies on the frequency and function of Tregs remains unclear. We examined the effect of anti-CD25 antibody, daclizumab, in vivo on Tregs in islet allograft recipients enrolled in a single-center study and monitored post-transplant. Our data shows that the reduction in CD25+ Treg cells observed post-transplant is due to masking of CD25 receptor by daclizumab and not due to depletion. In addition, using Treg marker, FoxP3, we show that anti-CD25+ ATG treatment leads to an increase in FoxP3+ Tregs post-transplant. These data suggest that anti-CD25-based therapy has beneficial effects on Tregs and combined with ATG may be a promising therapy for autoimmunity and transplantation.
链接:http://www.sciencedirect.com/science/article/pii/S0008874912000214
